Molecular Immunology Lab, Department of Immunology, Wilhelmina Children's Hospital, Utrecht, The Netherlands.
Blood. 2010 Feb 4;115(5):965-74. doi: 10.1182/blood-2009-02-207118. Epub 2009 Dec 7.
Regulatory T cells (Tregs) are a specific subset of lymphocytes that are critical for the maintenance of self-tolerance. Expression levels of the transcription factor Foxp3 have been causally associated with Treg differentiation and function. Recent studies show that Foxp3 can also be transiently expressed in effector T cells; however, stable Foxp3 expression is required for development of a functional Treg suppressor phenotype. Here, we demonstrate that Foxp3 is acetylated, and this can be reciprocally regulated by the histone acetyltransferase p300 and the histone deacetylase SIRT1. Hyperacetylation of Foxp3 prevented polyubiquitination and proteasomal degradation, therefore dramatically increasing stable Foxp3 protein levels. Moreover, using mouse splenocytes, human peripheral blood mononuclear cells, T cell clones, and skin-derived T cells, we demonstrate that treatment with histone deacetylase inhibitors resulted in significantly increased numbers of functional Treg cells. Taken together, our data demonstrate that modulation of the acetylation state of Foxp3 provides a novel molecular mechanism for assuring rapid temporal control of Foxp3 levels in T cells, thereby regulating Treg numbers and functionality. Manipulating Foxp3 acetylation levels could therefore provide a new therapeutic strategy to control inappropriate (auto)immune responses.
调节性 T 细胞(Tregs)是淋巴细胞的一个特定亚群,对于维持自身耐受至关重要。转录因子 Foxp3 的表达水平与 Treg 的分化和功能有因果关系。最近的研究表明,Foxp3 也可以在效应 T 细胞中短暂表达;然而,稳定的 Foxp3 表达对于发展功能性 Treg 抑制表型是必需的。在这里,我们证明 Foxp3 被乙酰化,这可以被组蛋白乙酰转移酶 p300 和组蛋白去乙酰化酶 SIRT1 相互调节。Foxp3 的高度乙酰化可防止多泛素化和蛋白酶体降解,从而显著增加稳定的 Foxp3 蛋白水平。此外,使用小鼠脾细胞、人外周血单核细胞、T 细胞克隆和皮肤衍生的 T 细胞,我们证明组蛋白去乙酰化酶抑制剂的处理导致功能性 Treg 细胞数量显著增加。总之,我们的数据表明,Foxp3 乙酰化状态的调节提供了一种新的分子机制,可确保 T 细胞中 Foxp3 水平的快速时间控制,从而调节 Treg 的数量和功能。因此,操纵 Foxp3 的乙酰化水平可能为控制不适当的(自身)免疫反应提供一种新的治疗策略。
PLoS One. 2011-4-20
Cells. 2025-4-8
Immune Netw. 2025-2-24
Front Immunol. 2025-1-15
Cancers (Basel). 2024-4-22